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Abstract
Background: The role of TCF/b-catenin signalling in T cell development is well established, but important roles in mature T
cells have only recently come to light.
Methodology/Principal Findings: Here we have investigated the signalling pathways that are involved in the regulation of
b-catenin in primary human T cells. We demonstrate that b-catenin expression is upregulated rapidly after T cell receptor
(TCR) stimulation and that this involves protein stabilisation rather than an increase in mRNA levels. Similar to events in Wnt
signalling, the increase in b-catenin coincides with an inhibition of GSK3, the kinase that is required for b-catenin
degradation. b-catenin stabilisation in T cells can also be induced by the activation of PKC with phorbol esters and is
blocked by inhibitors of phosphatidylinositol 3-kinase (PI3K) and phospholipase C (PKC). Upon TCR signalling, b-catenin
accumulates in the nucleus and, parallel to this, the ratio of TCF1 isoforms is shifted in favour of the longer b-catenin
binding isoforms. However, phosphorylated b-catenin, which is believed to be inactive, can also be detected and the
expression of Wnt target genes Axin2 and dickkopf is down regulated.
Conclusions/Significance: These data show that in mature human T cells, TCR signalling via PI3K and PKC can result in the
stabilisation of b-catenin, allowing b-catenin to migrate to the nucleus. They further highlight important differences
between b-catenin activities in TCR and Wnt signalling.
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Introduction
Wnt/b-catenin signalling is important for cell fate decisions
during many developmental programs. The canonical Wnt
signalling pathway is initiated upon binding of Wnt to the
receptor Frizzled and its co-receptor LRP, which ultimately leads
to the stabilisation and accumulation of b-catenin. Stabilised b-
catenin translocates to the nucleus and associates with the
transcription factors TCF and LEF to drive transcription of Wnt
regulated genes [1,2]. In the absence of a Wnt signal, b-catenin
associates with a destruction complex comprising the kinases
glycogen synthase kinase 3 (GSK3) and casein kinase 1 (CK1), and
the scaffolding proteins Axin and adematosis polyposis coli (APC).
This interaction results in the phosphorylation of b-catenin at its
N-terminus by GSK3/CK1, which serves as a recognition signal
for ubiquitination by the SCF E3 ligase bTrCP and leads to the
degradation of b-catenin by the proteasome [2]. Thus, the
regulation of b-catenin stability is key to Wnt signalling. Mutations
in the N-terminal phosphorylation sites of b-catenin and in the b-
catenin destruction complex proteins Axin and APC are found in
multiple cancers, suggesting that strict regulation is essential to
avoid malignancies [2].
Wnt/b-catenin signalling regulates many aspects of T cell
development [3,4] but its role in mature T cells is less clear. Early
reports suggested a lack of b-catenin expression and transcriptional
activity in peripheral human T cells [5] and a failure of GSK3
inhibition to induce TCF/b-catenin dependent transcription in
the Jurkat T cell line [6,7]. However, recent data have
demonstrated several important roles for TCF1/b-catenin in
mature T cell differentiation and function. For murine CD4+ T
cells, the expression of high levels of a stable form of b-catenin in
Treg cells was shown to increase cell survival, resulting in an
enhanced protection against inflammatory bowel disease in a
mouse model [8]. In the same report it was demonstrated that
retroviral expression of stable b-catenin in naı ¨ve CD4
+ T cells
renders these cells anergic [8]. More recently, Sen and co-workers
[9] have shown that TCF1 and b-catenin play a critical role in
TH2 differentiation. TCF1/b-catenin were found to activate the
transcription of GATA-3-1b early after TCR activation. Further-
more, in activated effector T cells, b-catenin has been shown to
regulate expression of matrix metalloproteinases MMP2 and
MMP9 during T cell extravasation, which promotes migration
through subendothelial basement membrane [10]. Finally, several
studies have demonstrated an important role for TCF1/b-catenin
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[11,12,13]. Most notably, the expression of a stabilised b-catenin
transgene was shown to promote the induction of CD8+ memory
T cells, whereas the absence of TCF1 or b-catenin resulted in a
defect in central CD8+ memory T cell differentiation [13].
Consistent with a role for TCF1/b-catenin in mature T cells, a
dynamic regulation of the multiple isoforms of TCF that arise from
alternative splicing and alternative promoter usage [14] upon
activation of naı ¨ve and memory CD8
+ T cells has also been
demonstrated [15]. Despite these reports there is little information
on how b-catenin is regulated in T cells, but studies on immature
and mature mouse T cells have suggested that pre-TCR and TCR
signalling can stabilise b-catenin [16,17,18,19]. An obvious player
in this pathway is GSK3, an unusual kinase that it is constitutively
active in the absence of a signal. TCR signalling is known to
inhibit GSK3 and this controls the localisation of the transcription
factor NFAT in the nucleus [20]. Here, we have examined the
expression pattern of b-catenin in primary human T cells
following activation through the TCR. We report that b-catenin
is post-transcriptionally regulated by TCR signalling and that this
occurs in a protein kinase C (PKC) and phosphatidylinositol 3-
kinase (PI3K) dependent fashion.
Results
TCR signalling up-regulates b-catenin in primary human
T Cells
Signalling via the TCR in combination with CD28 is known to
inhibit GSK3 [21] which could lead to an increase in the
expression of b-catenin. To investigate this, human primary T cells
were isolated, stimulated with agonist antibodies to the TCR
complex and b-catenin expression was analysed by Western
blotting. b-catenin was virtually undetectable in unstimulated cells,
but the protein was upregulated as early as 2 hours after TCR
stimulation (Figure 1A). The levels of b-catenin further increased
with time, peaked around 8 hours, and were still enhanced after
72 hours of stimulation (Figure 1A). This increase in b-catenin was
efficiently abolished when T cells were transfected with siRNA
against b-catenin prior to T cell stimulation (Figure 1B). Thus,
these experiments reveal that b-catenin is rapidly up-regulated in
response to TCR stimulation.
To investigate whether b-catenin up-regulation occurs at the
mRNA or protein level, we monitored b-catenin mRNA levels in
stimulated T cells by qRT-PCR. T cell activation had little impact
on b-catenin mRNA levels over a range of time points (Figure 1C),
despite increased protein expression within the same population of
T cells (Figure 1A). Therefore, we conclude that up-regulation of
b-catenin downstream of TCR signalling does not result from an
increase in b-catenin mRNA levels, but reflects changes in post-
transcriptional events such as protein translation or protein
stability. During the course of these experiments, we also
considered the expression of a-catenin and found that levels of
this protein also increased over time following TCR stimulation
(Figures 1A). However, in contrast to the result with b-catenin, the
enhanced a-catenin protein levels resulted from an increase in
mRNA levels as detected by qRT-PCR (Figure 1C).
b-catenin protein levels are enhanced through GSK3
inactivation
In the absence of a signal, levels of b-catenin are low because of
its phosphorylation on residues Ser33/37 and Thr41 [2] by the
constitutively active kinase GSK3, which targets b-catenin for
ubiquitination and subsequent proteasomal degradation. Wnt
signalling leads to the inactivation of GSK3 and thus the
accumulation of active, nuclear b-catenin. We investigated
whether similar events are involved in the increase in b-catenin
levels in response to anti-CD3/CD28 antibody stimulation. GSK3
inhibition was monitored by GSK3 phosphorylation on inhibitory
residues Ser21 (GSK3a) and Ser9 (GSK3b) as this is known to
correlate with a reduction in GSK3 activity [22]. Stimulation with
anti-CD3/CD28 antibodies indeed resulted in increased phos-
phorylation of GSK3a/b (Figure 2, lane 2). As a control in these
experiments we included lithium, which directly inhibits GSK3
[23]. The levels of b-catenin protein detected following overnight
stimulation with anti-CD3/CD28 were comparable to those in
cells treated with 20 mM lithium (Figure 2, compare lanes 2 and
6), a standard concentration reported to stabilise b-catenin in
other cell types [24]. Consistent with this, the phosphorylation of
GSK3a/b in CD3/CD28 stimulated cells was also comparable to
that in T cell cultures exposed to 20 mM lithium (Figure 2, lanes 2
and 6). Unexpectedly, despite the apparent inhibition of GSK3a/
b after T cell stimulation, b-catenin phosphorylated on Ser33/37
and Thr41 was detectable in anti-CD3/CD28 stimulated cells
(Figure 2, lane 2). Moreover, time course experiments showed that
these phosphorylated forms appear with similar kinetics as total b-
catenin (see Figure 3A).
The presence of lithium and anti-CD3/28 stimulation together
enhanced b-catenin levels relative to that observed with either
anti-CD3/CD28 or lithium alone (Figure 2, lane 10 versus lanes 2
and 6). The combined presence of anti-CD3/CD28 and lithium
also further increased the phosphorylation of GSK3 and led to an
Figure 1. TCR signalling increases the level of b-catenin. T cells
were stimulated with anti-CD3 antibodies for the indicated times. (A)
Cell aliquots were analysed for expression of a-catenin or b-catenin
protein levels by Western blotting. Western blotting with anti-ERK was
used to control for protein loading. (B) Antibody specificity was
confirmed by transfecting T cells with control RNAi (Luciferase) or RNAi
directed against b-catenin (Ctnnb1) prior to T cell stimulation for
18 hours. (C) mRNA levels for a-catenin (Ctnna1) and b-catenin (Ctnnb1)
were measured by qPCR relative to expression of 18srRNA (endogenous
control). Two independent experiments are shown for comparison.
Experiments were performed in triplicate with similar results obtained
when compared against alternative endogenous controls actin, GAPDH
and HPRT (not shown). The cells used in Expt1 were used for Western
blotting in (A).
doi:10.1371/journal.pone.0012794.g001
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additive effect of lithium suggests that GSK3 may not be
completely inhibited following stimulation via the TCR. However,
lithium has a dual effect on GSK3: it directly inhibits GSK3
activity by competing with Mg
2+ and can further enhance GSK3
inhibition by reducing the activity of phosphatases that dephos-
phorylate Ser21 (GSK3a) and Ser9 (GSK3b) [23,25]. Moreover,
lithium has been shown to inhibit other protein kinases as well.
Therefore, we also compared the effect of TCR activation on b-
catenin levels with that of an alternative inhibitor of GSK3, the
ATP-competitor BIO-acetoxime (BIO-ac, also called GSK3
inhibitor X). BIO-ac is a more selective analogue of 6-
bromoindirubin-32-oxime (BIO) that exhibits greater selectivity
for GSK3 than lithium. BIO-ac robustly induced b-catenin
stabilisation in primary human T cells. However, T cell activation
in combination with BIO-ac had no additive effect on b-catenin
levels. This likely reflects the greater potency of BIO-ac over
lithium, resulting in maximum inhibition of GSK3 and therefore
greater induction of b-catenin levels.
In summary, we conclude that the increase in b-catenin levels
upon TCR signalling correlates with GSK3 inhibition, suggesting
that it results from a stabilisation of the b-catenin protein. The
residual phosphorylation of this stabilised b-catenin may arise
from an incomplete inactivation of GSK3.
The induction of b-catenin occurs in parallel with a
modulation of TCF isoforms
Primary T cells have been shown to express full length and short
isoforms of the transcription factor TCF1 in equivalent amounts
(Figure 3A) [15]. Of these, the N-terminally truncated, short TCF1
isoforms can bind to DNA but cannot interact with b-catenin and
are known to antagonise b-catenin signalling [14]. When primary
human T cells were activated through the TCR, a gradual
decrease in the relative levels of the short TCF1 isoforms was
observed with time, resulting in the virtual absence of these forms
at 24 hours post stimulation (Figure 3A). This down-modulation
was transient and a complete re-expression of short TCF1 isoforms
was seen at 72 hours after TCR activation.
To explore the stabilisation of b-catenin and modulation of
TCF1 isoforms further, we next isolated populations of CD4+ and
CD8+ T cells and divided these into naı ¨ve and memory subsets
based on the surface expression of CD45 isoforms (Figure 3B).
Stimulation via the TCR showed that levels of b-catenin were
similarly induced in CD4+ and CD8+ T cells and that this
Figure 2. GSK3 regulates the expression of b-catenin down-
stream of TCR signalling. (A) Primary human T cells were left
unstimulated (lane 1) or stimulated for 18 hours with plate bound anti-
CD3 and anti-CD28 antibodies (lane 2), or with increasing concentra-
tions of LiCl (0, 0.2, 2 or 20 mM, indicated by black triangles, lanes 3–6),
or with anti-CD3/CD28 and increasing LiCl concentrations together
(lanes 7–10). Total cell lysates were immunoblotted with antibodies
specific for b-catenin, phospho-b-catenin (Ser33/37/Thr41, herein
referred to as p-b-catenin), phospho-GSK3a/b (Ser21/9, herein referred
to as p-GSK3a/b) and GSK3. (B) T cells were stimulated for 18 hours with
plate-bound anti-CD3 as indicated, either in the absence or presence of
the GSK3 inhibitor Bio-ac at 1 mM. Total cell lysates were analysed by
Western blot with anti-b-catenin. An anti-tubulin blot is shown as a
control for protein loading. This experiment was repeated twice with
similar results.
doi:10.1371/journal.pone.0012794.g002
Figure 3. Induction of b-catenin correlates with a modulation of
TCF1 isoform usage. (A) T cells were stimulated with plate bound
anti-CD3 and anti-CD28 antibodies for the indicated times and
immediately frozen as dry pellets on dry ice. Total cell lysates were
prepared and run on SDS-PAGE, immunblotted for b-catenin, phospho-
b-catenin and TCF-1. Total ERK expression served as a loading control.
(B) T cells were fractionated based on the expression of CD4 and CD8 as
well as CD45 isoform expression (CD45RA: naı ¨ve T cells or CD45RO:
memory T cells) as outlined in materials and methods. The cells were
either left unstimulated or were stimulated overnight with anti-CD3/
CD28 antibodies. Total cell lysates were immunoblotted for b-catenin
and TCF1.
doi:10.1371/journal.pone.0012794.g003
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(CD45RA+) or memory (CD45RO+) T cells were studied.
Moreover, the expression and modulation of TCF1 isoforms
following activation was also observed for all T cell population to a
similar extent (Figure 3B). Taken together we conclude that T cell
activation stabilises b-catenin and changes the ratio of TCF1
isoforms in favour of the full length, b-catenin binding isoforms.
TCR signalling drives nuclear accumulation of b-catenin
but target genes are downmodulated
When b-catenin is stabilised following Wnt signalling, the de-
phosphorylated ‘active’ b-catenin translocates to the nucleus and
associates with TCF/LEF proteins to drive transcription of TCF/
LEF dependent genes. We explored whether nuclear translocation
of b-catenin also occurred following T cell activation. Following
overnight incubation with various stimuli, T cell homogenates
were separated into cytoplasmic and nuclear fractions, the purity
of which was demonstrated by Western blotting for the
cytoplasmic protein tubulin and the nuclear protein lamin B1
(Figure 4). In T cells stimulated with anti-CD3/CD28, a
considerable fraction of b-catenin could be detected in the
nucleus, similar to that observed following lithium treatment
(Figure 4). The presence of both anti-CD3/28 and lithium resulted
in the highest relative amount of b-catenin in the nucleus. When
cells were stimulated with anti-CD3/CD28, phosphorylated forms
of b-catenin were found in the nucleus, which is surprising given
that b-catenin is thought to be active in the dephosphorylated
form [26]. Nevertheless, these results show that like Wnt signalling,
TCR signalling leads to nuclear localisation of b-catenin. To
monitor whether this presence of b-catenin in the nucleus resulted
in an increase in TCF/b-catenin transcriptional activity, we
measured induction of known Wnt target genes at several time
points after T cell activation (list of Wnt target genes available
from http://www.stanford.edu/ ˜rnusse/wntwindow.html). A ro-
bust increase in mRNA levels of CD25 (the IL-2 receptor a-chain)
with anti-CD3/CD28 stimulation, demonstrated that efficient T
Figure 4. TCR stimulation leads to nuclear translocation of b-catenin. (A) T cells were stimulated with plate bound anti-CD3/CD28 in the
presence or absence of 20 mM LiCl for 18 hours, as indicated, following which cytoplasmic and nuclear fractions were separated. Fractions were
immunoblotted for b-catenin and phospho-b-catenin expression. Cytoplasmic and nuclear fractionation was confirmed by tubulin (cytosol) and
lamin-B1 (nuclear) expression. (B) T cells were stimulated with anti-CD3/CD28 magnetic beads for the indicated times. CD25 (IL-2Ra) mRNA levels
were measured by qRT-PCR, using Abl1 as an internal control, to verify successful T cell activation. (C) The expression of the TCF/b-catenin target
gene Axin2 was measured by qRT-PCR following stimulation of T cells with anti-CD3/CD28 (same samples as in B). (D) In parallel to the samples in B
and C, T cells and HEK293T cells were left untreated or incubated with 20 mM lithium for 7 hours and measured for Axin2 mRNA levels relative to
those of Abl1. (E) Left: T cells were stimulated with anti-CD3/CD28 for the indicated times and Axin2 and DKK-1 mRNA levels were determined by
qRT-PCR relative to Abl and PPIA. The expression relative to Abl1 is shown, with calculations relative to PPIA yielding comparable results. Right:
HEK293T cells were left untreated or incubated with 20 mM lithium for 7 hours and measured for DKK-1 mRNA levels relative to those of Abl1. All
qRT-PCR reactions were performed in triplicate.
doi:10.1371/journal.pone.0012794.g004
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the expression of Axin2 as a well-characterized TCF/b-catenin
target. Surprisingly, T cell activation resulted in the down
modulation of Axin2 mRNA levels as measured by qRT-PCR
(Figure 4C). On the other hand, the parallel treatment of T cells
with lithium resulted in an up-regulation of Axin2 mRNA levels,
comparable to that in HEK293T cells, indicating that a TCF/b-
catenin dependent increase in expression of this gene does occur in
primary human T cells (Figure 4D). Similarly, we found that in a
separate experiment another target of Wnt/TCF signalling,
Dickkopf (DKK-1) was also down regulated by TCR signalling
(Figure 4E, left), despite this gene being upregulated in lithium-
treated HEK293T cells (Figure 4E, right). We conclude that T cell
activation appears to affect certain TCF/b-catenin target genes
resulting in their down regulation. It is noted that both Axin2 and
DKK-1 are known negative regulators of Wnt signals.
PKC and PI3K regulate GSK phosphorylation and
b-catenin levels downstream of the TCR
To probe further the signals required to induce b-catenin up-
regulation in T cells, T cell cultures were treated with a variety of
compounds and stimuli (Figure 5A). The addition of the
proteasome inhibitor MG132 increased levels of b-catenin as
well as that of phospho-b-catenin (Figure 5A, lane 2), consistent
with the notion that b-catenin levels are normally low because of
proteasomal degradation upon phosphorylation by GSK3. Next,
the effect of stimulation with either anti-CD3 or anti-CD28
separately was compared to that of anti-CD3 and anti-CD28
combined. The results showed that anti-CD3 stimulation at
10 mg/ml is sufficient to increase b-catenin levels (Figure 5A, lane
4). Anti-CD28 on its own had no effect (Figure 5A, lane 5) nor
did it increase the amount of b-catenin induced in the presence of
this concentration of anti-CD3 (Figure 5A, compare lanes 4 and
6). Levels of b-catenin phosphorylation were also similar for anti-
CD3 and anti-CD3/CD28 stimulated T cells (Figure 5A, lanes 4
and 6). However, the use of this high concentration of plate
bound anti-CD3 antibody could have masked potential effects of
CD28 activation. Therefore, we repeated these experiments using
graded doses of plate bound anti-CD3 stimulation. Interestingly,
effects of anti-CD28 could be visualised when the concentration
of CD3 was reduced to 1 mg/ml (not shown) or 0.1 mg/ml
(Figure 5B), resulting in higher b-catenin levels in the presence of
anti-CD28.
CD28 ligation initiates PI3K activation [27], which activates
AKT leading to GSK3 phosphorylation and inactivation. Consis-
tent with this, higher levels of pGSK3 phosphorylation were
observed in the presence of anti-CD28 when cells were stimulated
with a low dose of anti-CD3 (Fig. 5B). Robust stimulation with anti-
CD3 alone is also known to induce PI3K dependent AKT
activation and consequently GSK3 inactivation [28]. To determine
whether activation of PI3K plays a role in the increase in b-catenin
levels after T cell activation, T cells were treated with the PI3K
inhibitor LY294002 before and during stimulation. Indeed,
LY294002 treatment reduced anti-CD3 induced GSK3 phosphor-
ylation downstream of PI3K (Figure 5C, see also Figure 6B, D) as
well as AKT phosphorylation (not shown). Moreover, the increase
inb-cateninlevelswasalsodrasticallyreducedinthepresenceofthis
inhibitor (Figure 5C, Figure 6 B, D). On the other hand, the MEK
inhibitor PD98059 had no effect on the induction of either GSK3
phosphorylation or b-catenin levels (Figure 5C). These data suggest
that TCR signalling via PI3K/AKT and the resulting inactivation
of GSK3 lead to the stabilisation of b-catenin.
An induction of b-catenin levels could also be observed by
mimicking signalling downstream of the TCR with a combination
of the phorbol ester PDBu, a potent activator of PKC isoforms,
and the calcium ionophore ionomycin (Figure 6A). Separate
stimulation with either PDBu or ionomycin showed that treatment
with PDBu alone was sufficient to enhance b-catenin levels
(Figure 6A). Importantly, this PDBu mediated stabilisation of b-
catenin was not affected by the presence of the PI3K inhibitor
LY294002 (Figure 6B). PDBu treatment is known to induce GSK3
phosphorylation in a variety of cell types including B cells [29] and
similarly, treatment of T cells with PDBu induced GSK3
phosphorylation (Figure 6C). However, despite this apparent
GSK3 inhibition, phosphorylated b-catenin proteins were detect-
able following stimulation with PDBu (Figure 6A), as was
previously observed for cells stimulated with anti-CD3/CD28
(Figures 2A, 3A and 4A). Also similar to anti-CD3/CD28
stimulation, the effect of PDBu on b-catenin could be increased
by the addition lithium (Figure 6C). These effects of PDBu suggest
that PKC may also play a role in the stabilisation of b-catenin
downstream of TCR signalling. PDBu mimics diacylglycerol
(DAG), which is generated from the actions of phospholipase C
Figure 5. PI3K regulates the expression of b-catenin downstream of TCR signalling. (A) T cells were left untreated or were incubated for
18 hours with the proteasome inhibitor MG132, 20 mM LiCl, plate bound anti-CD3 (10 mg/ml), plate bound anti-CD28 (10 mg/ml), plate bound anti-
CD3 plus anti-CD28 (10 mg/ml each). Total cell lysates were used for Western blotting with anti-b-catenin, anti-phospho-b-catenin and anti-GSK3ab.
(B) T cells were stimulated for 18 hours with two different concentrations of plate-bound anti-CD3 in the absence or presence of anti-CD28. Total cell
lysates were analysed by Western blot with anti-b-catenin, anti-p-GSK3ab and anti-tubulin. This experiment was performed twice with similar results.
(C) T cells were pre-treated with the PI3K inhibitor Ly294002 (50 mM) or the MEK inhibitor PD98059 (50 mM) for 1 hour prior to 18 hours stimulation
with plate bound anti-CD3 in the presence of these inhibitors. Total cell lysates were immunoblotted with indicated antibodies.
doi:10.1371/journal.pone.0012794.g005
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activation of DAG-dependent isoforms of PKC. To address the
role of PKC in b-catenin stabilisation, and to avoid the use of PKC
inhibitors that may also target GSK3, we treated T cell cultures
with the PLC inhibitor U73122. T cell activation in the presence
of U73122 resulted in the inhibition of b-catenin stabilisation
comparable to that achieved by PI3K inhibition with 50 mM
Ly294002 (Figure 6D). Thus, this result indicates that downstream
of the TCR, PLC-DAG activates PKC resulting in an increase in
b-catenin levels. Taken together these data suggest that TCR
signalling via both PI3K and PKC play a role in the inactivation of
GSK3, which in-turn leads to the stabilisation of b-catenin.
Discussion
We explored the regulation of b-catenin expression in primary
human T cells and show that like in other cell types, b-catenin
levels are low in the absence of a signal owing to proteasome-
mediated degradation. However, upon T cell stimulation, a rapid,
post-transcriptional upregulation of b-catenin takes place, similar
to events that occur upon Wnt signalling. Activation of both PI3K
and PKC can induce the increase in levels of b-catenin, which
coincides with the phosphorylation and therefore inhibition of
GSK3, the kinase that normally targets b-catenin for degradation.
We further show that stabilised b-catenin can be detected in the
nucleus. Moreover, the expression of TCF1 isoforms were found
to be differentially regulated so that the longer b-catenin-
interacting forms predominate in the nucleus following T cell
activation. These data are consistent with important activities of
TCF/b-catenin in mature T cells such as the recently described
functions in T cell migration Treg function [8], memory T cell
differentiation [11,12,13], and the regulation of GATA3 expres-
sion during TH2 differentiation [9].
Although effects of Wnt on b-catenin in pre-activated T cells
have been demonstrated [10], our data indicate that b-catenin can
be regulated directly downstream of TCR signalling. Firstly, we
show that b-catenin up-regulation is rapid and can be detected
within 2 hrs of T cell activation (Figures 1 and 3). The
involvement of Wnts in this scenario would require an induction
of wnt genes downstream of the TCR and the subsequent
signalling through Frizzled receptors, which is unlikely to occur
within this time frame. Secondly, we show that b-catenin
upregulation can be blocked by Ly29004 (Figure 5), an inhibitor
of PI3K that is activated downstream of the TCR and is not
thought to be involved in Wnt signalling [30]. Furthermore, we
did not observe effects on b-catenin levels when biologically active
Wnt3a conditioned media or recombinant Wnt3a was added to
freshly isolated unstimulated cells (data not shown). Nevertheless, it
is possible that external Wnt can cooperate with TCR signals at
later stages and augment the inhibition of GSK3. Similar to the
additive effects observed with lithium (Figure 2) [24], this could
further enhance b-catenin levels and decrease b-catenin phos-
phorylation. Indeed, Wnt3a has been reported to stabilise b-
catenin in effector T cells and inhibit the proliferation of activated
CD8+ T cells [11].
PI3K appears to play a role in the stabilisation of b-catenin via
the activation of AKT that in turn inactivates GSK3 proteins. The
fact that Jurkat T cells, which are deficient in the PIP3
phosphatase PTEN that inactivates AKT, express high levels of
Figure 6. PKC can also regulate the expression of b-catenin. (A) T cells were incubated for 18 hours with either Ionomycin (I, 100 nM), PDBu
(P, 10 ng/ml), or a combination of PDBu and Ionomycin (P+I). Total cell lysates were used for Western blotting with anti-b-catenin, anti-phospho-b-
catenin and anti-GSK3. (B) T cells were stimulated for 18 hours with either anti-CD3 or PDBu in the absence or presence of the PI3K inhibitor
Ly294002. Total cell lysates were analysed by Western blot with anti-b-catenin and anti-phospho-GSK3. (C) T cells were stimulated for 18 hours with
either plate-bound CD3 (CD3), lithium (Li+) or PDBu (P), as shown, and analysed by Western blot with the antibodies indicated. (D) T cells were
stimulated with anti-CD3 for 18 hours either in the absence or presence of the PI3K inhibitor Ly294002 (20 and 50 mM) or the PLC inhibitor U73122
(10 mM). Total cell lysates were analysed by Western blot with anti-b-catenin, anti-p-GSK3a/b and anti-tubulin. A representative figure of two
experiments is shown.
doi:10.1371/journal.pone.0012794.g006
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this finding [5, and data not shown]. Furthermore, the
dysregulation of AKT may also explain the lack of lithium
induced TCF/b-catenin transcriptional activity that has been
reported for Jurkat cells [7]. We demonstrate that the activation of
PKC by phorbol esters can increase b-catenin levels as well, and
that PLC inhibitors inhibit this induction (Figure 6). Interestingly,
such a dual involvement of PI3K and PLC/PKC was also
demonstrated for the stabilisation of b-catenin in B cells following
B cell receptor triggering [29] and may reflect a role of PI3K in
the activation of PLC. For both PI3K and PKC pathways, the
inactivation of GSK3 appears to be the central event in the
stabilisation of b-catenin.
A surprising observation was the presence of phosphorylated b-
catenin following T cell activation. The fact that the GSK3
inhibitor lithium blocked this phosphorylation suggests that TCR
signalling does not completely inactivate GSK3. Indeed, it has
been shown that the combination of phorbol ester and ionomycin
decreases GSK3 activity by approximately 50% in T cells, and
that this inhibition is transient despite persistent stimulation [7,31].
Unexpectedly, the phosphorylated forms of b-catenin were
detected over a long period of time (72 hours, Figure 3) even
though N-terminal phosphorylation normally targets b-catenin for
ubiquitin-mediated proteasomal degradation. It is possible that T
cell activation inhibits to some extent components of the b-catenin
destruction pathway, but this has not yet been established.
Another unexpected finding was the presence of phosphorylated
b-catenin in nuclear fractions (Figure 4). This could result from the
nuclear translocation of phosphorylated b-catenin, or the
phosphorylation of b-catenin in the nucleus by GSK3, which
has been demonstrated to regulate NFAT [20] and CyclinD1 [32]
in this compartment. The role of this nuclear phosphorylated b-
catenin is not yet clear. It has been shown that phosphorylated b-
catenin can interact with LEF-1 but cannot form a ternary
complex with DNA [33] and cannot drive TCF reporter activity
[26]. However, a functional role of phosphorylated b-catenin in
the nucleus remains possible as well. Indeed, one study has
demonstrated that phosphorylated b-catenin localises to centro-
somes and may regulate the microtubule organizing centre [34].
Despite several attempts using Western blotting and immuno-
fluoresence we were unable to detect active b-catenin with an
antibody specific to the non-phosphorylated protein (data not
shown). We do not exclude that active non-phosphorylated b-
catenin is present but the levels of this protein may be below the
detection limits of this reagent. Nevertheless, the presence of
phosphorylated nuclear b-catenin indicates that different pathways
are operational downstream of TCR signalling compared to Wnt
signalling.
Transcriptional activity of TCF1/b-catenin early after T cell
stimulation has been demonstrated [9]. Consistent with this, we
found that TCF1 transcripts are regulated upon T cell activation
so that the b-catenin binding forms become the most abundant
(Figure 3 and [14]). Surprisingly, our data also revealed that
mRNA levels of the TCF/b-catenin target genes Axin2 and DKK-1
were reduced upon TCR activation. Axin2 and DKK-1 are
inhibitors of Wnt signalling and it is possible that an active
inhibition of these antagonists renders T cells more sensitive to
Wnt signalling at a later stage after T cell activation. Whereas this
remains to be determined, the down regulation of these TCF/b-
catenin targets again clearly demonstrates that the functions of b-
catenin after TCR signalling do not necessarily mimic those
described for the Wnt signalling pathway.
Another b-catenin partner, a-catenin, was also found to be
upregulated upon TCR signalling (Figure 1), which to our
knowledge has not been described before. A complex of a-catenin
and b-catenin plays a role in cell-cell adhesion downstream of the
adhesion molecule cadherin. In the absence of an established role
for cadherin in T cells, it will be interesting to determine the
function of this enhanced a-catenin. Interestingly, a-catenin
knockout keratinocytes display hyperpoliferative responses with
hyperactive RAS/MAPK signalling, suggesting that a-catenin
may play a role in processes other than adhesion [35].
In summary, our data provide new insights into the regulation
of b-catenin in response to TCR signalling in peripheral human T
cells, and reveal remarkable discrepancies between the activity of
TCF/b-catenin in Wnt and TCR signalling. This provides an
important basis for further studies into the various roles that have
emerged for b-catenin in mature T cells, keeping in mind that
these functions may also to a large extent be influenced by the
differentiation state of the cells.
Materials and Methods
Reagents
Chemicals were from Sigma-Aldrich unless otherwise indicated.
T cell isolation, stimulation and drug treatment
Primary human PBMCs were isolated from buffy coats
(National Blood Service) using Lymphoprep (Axis-Shield) and
density-gradient centrifugation. T cells were purified on nylon
wool (Kisker) columns yielding about 85–90% pure populations. T
cells were maintained in RPMI-1640 (Invitrogen), 10% FCS
(Helena Biosciences) and the antibiotics Penicillin (100 U/ml)/
Streptomycin (0.1 mg/ml streptomycin) (Gibco Ltd.) and used for
experiments within 24 hours of isolation. Alternatively, nylon wool
purified T cells were immunostained with APC conjugated anti-
CD4, PerCP conjugated anti-CD8, FITC conjugated anti-
CD45RA and PE conjugated anti-CD45RO (eBiosciences) on
ice for 1 hour in PBS 0.2% BSA. Cells were sorted on Becton
Dickinson Aria Flow Cytometer and immediately processed.
T cells (2–5610
6) were stimulated with plate-bound anti-CD3
and anti-CD28 antibodies (10 mg/ml each, unless otherwise stated)
for the indicated times. Where applicable, inhibitors of PI3K
(LY29002, Cell Signalling Technology), PLC (U73122, Calbio-
chem), GSK3 (Bio-acetoxime, also called GSK-3 inhibitor X,
Calbiochem) and MEK1/2 (PD98059, Calbiochem) were added
1 hour prior to stimulation and remained present during
stimulation. PDBu was used at 10 ng/ml and ionomycin at
100 nM. LiCl was added from a 8M stock solution to the indicated
final concentrations.
RNAi
To confirm antibody specificity, T cells were transfected at
5610
6 cells with 50 pmoles ON-TARGET plus siRNA targeting
human b-catenin (Ctnnb1), or control (Luciferase) siRNA reagents
(Thermo Fisher Scientific, Lafayette, CO). T cell transfections
were performed using the human T cell nucleofector reagent
(Amaxa biosystems) and programme U14 of the Amaxa
nucleofector. Cells were stimulated and processed 18 hours after
transfections.
SDS-PAGE and Western blotting
Antibody stimulated T cells were removed from plates with PBS
containing 5 mM EDTA and lysed in ice cold lysis buffer (1% NP-
40, 50 mM Tris-Cl (pH 7.5), 150 mM NaCl, 10 mM NaF,
10 mM disodium pyrophosphate) together with a cocktail of small
protease and phosphatase inhibitors (Roche). Equal amounts of
post-nuclear supernatants (BCA assay) were subjected to SDS-
Stabilisation of b-Catenin
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visualised with enhanced chemiluminescence (Pierce). To separate
nuclear and cytoplasmic fractions, T cells were lysed using the NE-
PER Extraction Reagents (Pierce) according to the manufacturer’s
instructions.
Antibodies
The following antibodies were used for immunoblotting: anti-b-
catenin, anti-phospho-b-catenin (Ser33/37/Thr41), anti-TCF-1,
anti-phospho-GSK3ab (Ser21/9), anti-phospho-AKT (Ser473) (all
Cell Signaling Technology), anti-GSK3ab (Biosource), anti-lamin
B1, anti-ERK1 (Santa Cruz Biotechnology), anti-tubulin (Invitro-
gen) and rabbit anti-a-catenin (VB1, [36] kind gift of V. Braga,
Imperial College, London, UK).
Quantitative real time PCR (qRT-PCR)
Isolated T cells were stimulated with plate bound anti-CD3 or
anti-CD3/CD28 magnetic beads (Dynal) for the indicated time
points, washed in cold PBS, pelleted and snap frozen in liquid
nitrogen as dry cell pellets. Total RNA was isolated using Trizol
(Invitrogen) and equivalent amounts reverse transcribed with the
high capacity cDNA reverse transcription kit (Applied Biosystems).
PCR was performed in triplicate in TaqMan Universal PCR
master mix containing gene specific probes or endogenous control
(Applied Biosystems). Ctnna1 (a-catenin) and Ctnnb1 (b-catenin)
gene expression were analysed using the ABI PRISM 7900HT
instrument and samples normalised to expression of endogenous
control. Fold increase was calculated by the DDCt method. Axin2
and DKK-1 mRNA levels were analysed using SYBR green PCR
mastermix (Applied Biosystems) and primers (Eurofins MWG
Operon) designed using the ProbeFinder software (Roche Applied
Science). Abl1 and PPIA were used as reference genes.
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